Accéder au contenu
Merck
  • Amphetamine concentrations in human urine following single-dose administration of the calcium antagonist prenylamine-studies using fluorescence polarization immunoassay (FPIA) and GC-MS.

Amphetamine concentrations in human urine following single-dose administration of the calcium antagonist prenylamine-studies using fluorescence polarization immunoassay (FPIA) and GC-MS.

Journal of analytical toxicology (2003-04-03)
Thomas Kraemer, Susanne K Roditis, Frank T Peters, Hans H Maurer
RÉSUMÉ

Prenylamine (R,S-N-(3,3-diphenylpropyl-methyl-2-phenethylamine), a World Health Organization class V calcium antagonist, is known to be metabolized to amphetamine. In this study, amphetamine concentrations after a single-dose administration of prenylamine were determined to check if they reached values that could be of analytical and/or pharmacological importance in clinical and forensic toxicology. Enantiomeric composition of amphetamine was also studied. Five volunteers received a single 120-mg oral dose of prenylamine. Urine samples were analyzed using the Abbott TDx immunoassay Amphetamine/Methamphetamine II and using our routine systematic toxicological analysis (STA) gas chromatography-mass spectrometry (GC-MS) procedure. For quantitation purposes, GC-MS was used in the selected-ion monitoring (SIM) mode (ions m/z 118, 122, 240, 244) after solid-phase extraction (Isolute Confirm HCX) and derivatization (heptafluorobutyric anhydride). Amphetamine-d5 was used as internal standard (IS). Chiral separation of the heptafluorobutyrated amphetamine enantiomers was achieved using an Astec Chiraldex G-PN column. The TDx results showed a great variability for the different volunteers. A urine sample of one volunteer showed results as high as 3200 ng/mL, whereas the urine samples of another volunteer never gave results greater than the TDx detection limit (100 ng/mL). Using the STA procedure, the presence of amphetamine could be confirmed in all urine samples with TDx results greater than the cutoff value (300 ng/mL). Using the GC-MS SIM method, amphetamine concentrations up to 1280 ng/mL were determined. Chiral analysis revealed that both enantiomers of amphetamine were present in the samples with a surplus of the S(+)-enantiomer in the early phase of excretion. Forensic implications are discussed.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
Colonne chirale pour CLHP Astec® CHIROBIOTIC® V, 5 μm particle size, L × I.D. 25 cm × 4.6 mm
Supelco
Astec® Chirobiotic® R Chiral HPLC Column, 5 μm particle size, L × I.D. 15 cm × 4.6 mm
Supelco
Astec® Chirobiotic® R Chiral HPLC Column, 5 μm particle size, L × I.D. 25 cm × 4.6 mm
Supelco
Astec® Chirobiotic® R Chiral HPLC Column, 5 μm particle size, L × I.D. 15 cm × 2.1 mm
Supelco
Astec® CHIRALDEX G-PN Capillary GC Column, L × I.D. 30 m × 0.25 mm, df 0.12 μm
Supelco
Astec® Chirobiotic® R Chiral HPLC Column, 5 μm particle size, L × I.D. 10 cm × 4.6 mm
Supelco
Colonne chirale pour CLHP Astec® CHIROBIOTIC® V, 5 μm particle size, L × I.D. 15 cm × 4.6 mm
Supelco
Colonne chirale pour CLHP Astec® CHIROBIOTIC® V, 5 μm particle size, L × I.D. 10 cm × 4.6 mm
Supelco
Colonne chirale pour CLHP Astec® CHIROBIOTIC® V, 5 μm particle size, L × I.D. 15 cm × 2.1 mm
Supelco
Astec® Chirobiotic® R Chiral HPLC Column, 5 μm particle size, L × I.D. 25 cm × 2.1 mm
Supelco
Astec® Chirobiotic® V Chiral HPLC Guard Column, Cartridge, 5 μm particle size, L × I.D. 2 cm × 4 mm
Supelco
Colonne chirale pour CLHP Astec® CHIROBIOTIC® V, 5 μm particle size, L × I.D. 10 cm × 2.1 mm
Supelco
Colonne chirale pour CLHP Astec® CHIROBIOTIC® V, 5 μm particle size, L × I.D. 25 cm × 2.1 mm